Nordea Investment Management AB Acquires 167,271 Shares of Pfizer Inc. $PFE

Nordea Investment Management AB grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,097,346 shares of the biopharmaceutical company’s stock after acquiring an additional 167,271 shares during the quarter. Nordea Investment Management AB’s holdings in Pfizer were worth $148,287,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Curio Wealth LLC increased its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Pfizer during the second quarter worth $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer during the second quarter worth $30,000. Darwin Wealth Management LLC acquired a new position in shares of Pfizer during the second quarter worth $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new position in shares of Pfizer in the 2nd quarter valued at $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $25.12 on Wednesday. The business has a 50-day moving average of $25.29 and a 200-day moving average of $24.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The company has a market capitalization of $142.83 billion, a price-to-earnings ratio of 14.60 and a beta of 0.47. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer’s dividend payout ratio is 100.00%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. HSBC reiterated a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $27.88.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: New oncology data showed a Pfizer cancer combination produced stronger tumor shrinkage versus standard treatment in advanced colorectal cancer — supportive for commercial/label expansion prospects in a high‑value oncology indication. Pfizer cancer combo shows strong tumor shrinkage in colorectal cancer trial
• Positive Sentiment: Pfizer advanced a lung‑cancer combo into a global Phase 2/3 program and launched a head‑to‑head colorectal cancer Phase 3 for PF‑08634404 — progress that de‑risks late‑stage oncology pipeline timing and future revenue potential. Pfizer advances new lung cancer combo in global Phase 2/3 trial
• Positive Sentiment: Positive data on Pfizer’s Braftovi regimen were reported, reinforcing the company’s targeted‑therapy franchise and near‑term oncology catalysts. Positive new data on Pfizer’s Braftovi regimen
• Positive Sentiment: CEO Albert Bourla signaled ambition to build an obesity consumer market comparable to Viagra’s consumer expansion; that, plus the $10B Metsera acquisition, positions Pfizer to capture a potentially large, recurring market if regulatory/launch execution succeeds. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: BMO reiterated a Buy and $30 price target, highlighting oncology, obesity pipeline upside and post‑LOE recovery prospects as key upside drivers. Pfizer: Underappreciated Growth Story
• Neutral Sentiment: Zacks’ preview of Q4 suggests oncology revenue will see steady growth from Seagen ADCs and key brands but be partially offset by pricing and competitive pressures — a mixed operational outlook ahead of earnings. Inside Pfizer’s Oncology Performance Ahead of Q4 Results
• Neutral Sentiment: Broker actions are mixed: UBS flagged the Metsera deal favorably but kept a Neutral stance ($25 PT), and the street average rating is around Hold — indicating uncertainty on near‑term revenue trajectory. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE Pfizer Receives Average “Hold” Rating
• Neutral Sentiment: Pfizer’s JPMorgan presentation material was published (slides/transcript) — useful for detail on strategy and pipeline but not an immediate stock mover absent new guidance. Pfizer Presents at J.P. Morgan Healthcare Conference
• Negative Sentiment: Pfizer stopped a mid‑stage lupus skin trial, removing a smaller autoimmune opportunity and signaling a pipeline setback that may reduce near‑term upside from non‑oncology indications. Pfizer Ends Mid-Stage Lupus Skin Trial
• Negative Sentiment: Analysts and commentators continue to flag legacy risks — a looming patent cliff, rising debt and earnings pressure post‑LOE — which cap valuation upside until clearer revenue recovery paths materialize. Pfizer’s Patent Cliff, Rising Debt, And The Fight To Stay A Buy

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.